Abstract
We performed preoperative chemotherapy with S-1 and low-dose CDDP (TSLD) to treat 9 patients of highly advanced gastric cancer. Five cases showed significant effect with severe fibrosis diagnosed as grade 1b-2 effect in histology, and all 9 cases showed at least grade 1a effect in either primary lesion or lymph node. While toxicity of less than grade 3 (gastrointestinal disorder and/or bone marrow suppression) were observed in 5 out of 9 cases (55.6%), no symptom was observed in 3 out of the 5 patients. We conclude that the TSLD is useful to control highly advanced gastric cancer.
Publication types
-
Case Reports
-
Clinical Trial
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / pathology
-
Adenocarcinoma / surgery
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cisplatin / administration & dosage
-
Drug Combinations
-
Female
-
Humans
-
Immunoenzyme Techniques
-
Lymph Nodes / pathology
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Oxonic Acid / administration & dosage
-
Pilot Projects
-
Preoperative Care
-
Pyridines / administration & dosage
-
Stomach / pathology
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / pathology
-
Stomach Neoplasms / surgery
-
Tegafur / administration & dosage
-
Treatment Outcome
Substances
-
Drug Combinations
-
Pyridines
-
S 1 (combination)
-
Tegafur
-
Oxonic Acid
-
Cisplatin